Granexin® Gel

Preclinical

Phase 1

Phase 2

Phase 3

Dermatology

Cutaneous Radiation Injury (CRI)

Granexin® Gel

Diabetic Foot Ulcer
(DFU)

Venous Leg Ulcer
(VLU)

Granexin gel pipeline

Granexin® Gel

Investigating 3 indications with unmet medical needs

Cutaneous Radiation Injury

Cutaneous Radiation Injury describes the impact high doses of radiation can have on the skin, and there are currently no drugs tailored to its treatment.

Diabetic Foot Ulcer

Diabetic Foot Ulcers (DFUs) are a common complication among the 37.3 million Americans impacted by diabetes. And for those who do not respond to available therapies, DFUs can result in lower extremity amputations.

Venous Leg Ulcer

Venous Leg Ulcers are the most common cause of leg ulcers, and a significant portion of them persist for more than 6 weeks, requiring chronic treatment.

Granexin® gel has demonstrated safety and efficacy in multiple preclinical and clinical studies.

This topical treatment has been evaluated in six clinical trials for the treatment of acute and chronic wounds. 

In clinical trials, Granexin® demonstrated:

Acceleration of wound healing

Slowed injury progression

Wound closure

Consistent safety and efficacy

Revolutionizing the Way the Body Responds to Injury

Xequel’s aCT1 technology platform is designed to stimulate healing by creating an improved injury response. Our proprietary aCT1 technology restores the gap junctions to normalize cell-to-cell signaling and facilitate proper healing.